Targeting Complement Pathways in Polytrauma- and Sepsis-Induced Multiple-Organ Dysfunction

Ebru Karasu¹, Bo Nilsson², Jörg Köhl³⁴, John D. Lambris⁵ and Markus Huber-Lang¹*

¹ Institute for Clinical and Experimental Trauma-Immunology, University Hospital of Ulm, Ulm, Germany, ² Department of Immunology, Genetics and Pathology (IGP), Laboratory CS, Uppsala University, Uppsala, Sweden, ³ Institute for Systemic Inflammation Research (ISEF), University of Lübeck, Lübeck, Germany, ⁴ Division of Immunobiology, Cincinnati Children’s Hospital, Cincinnati, OH, United States, ⁵ Department of Pathology & Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, United States

Exposure to traumatic or infectious insults results in a rapid activation of the complement cascade as major fluid defense system of innate immunity. The complement system acts as a master alarm system during the molecular danger response after trauma and significantly contributes to the clearance of DAMPs and PAMPs. However, depending on the origin and extent of the damaged macro- and micro-milieu, the complement system can also be either excessively activated or inhibited. In both cases, this can lead to a maladaptive immune response and subsequent multiple cellular and organ dysfunction. The arsenal of complement-specific drugs offers promising strategies for various critical conditions after trauma, hemorrhagic shock, sepsis, and multiple organ failure. The imbalanced immune response needs to be detected in a rational and real-time manner before the translational therapeutic potential of these drugs can be fully utilized. Overall, the temporal-spatial complement response after tissue trauma and during sepsis remains somewhat enigmatic and demands a clinical triad: reliable tissue damage assessment, complement activation monitoring, and potent complement targeting to highly specific rebalance the fluid phase innate immune response.

Keywords: trauma, sepsis, hemorrhagic shock, MODS, complement activation, complement dysregulation, complement therapeutics, clinical trial

INTRODUCTION

Complement activation as a major innate defense strategy occurs early after trauma, hemorrhagic shock and during sepsis in both the experimental and clinical settings (1–6). A recent comparison of severe trauma and septic patients in an intensive care unit (ICU) showed that during sepsis, excessive activation of the complement cascade is detectable as evidenced by significantly enhanced systemic C3a concentrations, whereas during trauma, complement activation is also existent but less pronounced (7). In trauma, rapid consumption of key complement components such as C3 or C5 seems to be the primary mechanisms (7) whereas in septic conditions, consumption of complement factors may occur later (if at all), secondary to the activation. Hyper-activated and consumed defense systems including the complement and coagulation cascade can result in imbalanced immune responses, impaired clearance of tissue debris and pathogens, dysregulated coagulation, perfusion disturbances, changes in tissue and cellular microenvironment, and barrier dysfunction. All these alterations culminate in multiple signaling-,
cellular- and organ dysfunction (8, 9). Although highly specific complement inhibitors are available, translation of these observations into therapeutic strategies remains challenging and requires differential considerations (10). The immune response to damaged and infected tissue is not mono-dimensional; instead it comprises various compartmentalized responses and organ specific outcomes (11, 12). For example, in experimental sepsis there is a loss of C5aR expression on neutrophils whereas C5aR expression on various organs is significantly enhanced (13). Thus, the complement reaction to danger associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) needs to be reliably determined before any specific therapeutic intervention can be applied in the clinical setting of severe sterile or infectious insults. Furthermore, underlying triggers and mechanisms of the multiple organ dysfunction syndrome (MODS) need to be detected and further explored. Several hypotheses exist about the initiators and drivers of MODS. Main contributors seem to be barrier failure (9), electrophysiological alterations (14), microcirculatory disturbances, inflammation-induced cell dysfunction, protein alterations and microbiome shifts (15). Hibernation seems to be a contributing factor in the development of MODS, which allows the cell to shut down energy consuming functional efforts and therefore to preserve the cellular morphology (16). Although MODS can be induced by distinct injuries and infectious insults, once established, it seems to follow common pathways. For the individual and also the society, MODS remains a major burden with a high lethality rate and a high socio-economic impact and therefore requires an improved understanding, comprehensive mechanistic insights and basic as well as clinical research efforts (17).

**POLYTRAUMA-INDUCED MODS—ROLE OF COMPLEMENT**

Polytrauma comprises life-threatening multiple injuries that activate innate and adaptive immunity with multidimensional consequences for the host (9, 18). Although some reduction in the frequency of MODS after polytrauma has been noted in the last decades, it still remains a major cause of death after severe trauma (19). Within minutes after polytrauma there is a significant increase in circulating complement activation products such as C3a, C5a, and sC5b-9 and a drop in complement hemolytic activity (2–4, 6, 20) (Figure 1). Of note, an enhanced C3a/C3 ratio in plasma early after trauma was prognostic for lethal outcome (6). Another study showed enhanced C3a levels as an indicator for MODS (20). Activation via its amplification by the alternative pathway is observed early after trauma measured by Bb plasma levels, which was additionally correlated with injury severity and the development of organ failure such as acute lung injury and acute renal failure (3). The underlying mechanisms, however, are still elusive. For example, C3a may have a direct pathophysiological impact on the lungs as an “engine” of multiple organ failure. C3a alters not only the microvascular and airway tonus (21) but induces direct pro-inflammatory effects (22) which may contribute to perfusion disturbances and cellular dysfunction. In a murine model of blunt thorax trauma, we have found enhanced C3 and heme-oxygenase-1 (HMOX1) transcriptional expression levels in the lungs early after injury (23). A recent analyses of 81 polytrauma patients also revealed an enhanced expression of HMOX1, which was associated with septic complications (24). In this context, it is noteworthy that HMOX1 is downregulated in leukemic leukocytes by C3a and C5a resulting in an enhanced cellular mobility and infectious complications (25), indicating some interaction between HMOX1 and complement activation processes. Clinical trials, evaluating the effect of targeting at the C3or C3a/C3aR are lacking. Although in a different context, a recent study showed the potential of HMOX1 to protect endothelial cells against heme-mediated complement activation. Heme activates the alternative complement pathway and also upregulates the cyto-protective and stress-response gene HMOX1 in an organ-specific manner. While it was highly upregulated in endothelial cells of large vessels, it was poorly upregulated in the renal endothelium, which makes the renal endothelium more vulnerably for complement over-activation and showed stronger C3 deposition (26).

On the C5 level, the generated anaphylatoxin C5a is a potent chemoattractant that enhances surface expression of intercellular adhesion molecules on the endothelium, and thereby effectively recruits inflammatory cells to the injured site (27). The migrated cells of the first line of defense can sense, phagocyte and clear damaged tissue and induced repair processes (9). In a recent polytrauma study, leukocytes with low C5-expression on day 1 after trauma correlated with an increased risk for the development of nosocomial infections during the later course (28). The corresponding C5a receptors, C5aR1 and C5aR2, are down-regulated on leukocytes early after trauma (29), something that has been proposed as a sign of enhanced risk for infectious complications (30). Of note, no clinical trial has been proposed or designed in regard to polytrauma using downstream modulation principals of the complement cascade, e.g., modulation of the membrane attack complex (MAC). This might represent an interesting pharmaceutical target, especially since significant amounts of sC5-9 are generated early after polytrauma (2).

**HEMORRHAGIC-SHOCK-INDUCED MODS—ROLE OF COMPLEMENT**

Hemorrhagic shock is a condition of disturbed tissue perfusion, resulting in the inadequate delivery of oxygen and nutrients and inadequate clearance of waste products, all of which are vital for regular cellular function. The involvement of complement is complex.

Complement activation products have been reported to directly or indirectly alter the vascular tonus. A C3a-analag
peptide was able to cause pulmonary artery constriction in a thromboxane-dependent manner (31). Similarly, C5a caused transient vasoconstriction of an isolated pulmonary artery, which was dependent on the integrity of the endothelium (32). In other reports, C5a caused a leukocyte-dependent vasospasm and triggered thromboembolic events by C5a-induced release of thromboxane-like eicosanoids (33). In line with this observation, C5a is involved in the pathogenesis of acute kidney injury in hemorrhagic shock by reducing renal blood flow by ~ 30% and the glomerular filtration rate by ~ 45%, respectively (34). Of note, when either a leukotriene antagonist was applied or neutrophils were depleted, the C5a-induced reduction in renal perfusion was not observed indicating a leukotriene-dependent (34). In contrast, systemic application of C5a in rabbits induced a reversible drop in systemic arterial pressure (MAP) and a drop in central venous pressure (CVP), decreased cardiac output (CO), and neutropenia (35). In regard to coronary artery vasotonus, conflicting data have been reported for C5a both, vasoconstrictory (36) and vasodilatory effects (37). Other studies concluded that anaphylatoxins alter the vascular tone with a high variability depending on the localization and pre-exposure to other mediators (38). Taken together, the available data suggest that complement activation changes tissue perfusion by macro- and micro-hemodynamic effects, especially when a shock is already established.

Another central pathomechanistic driver of hemorrhagic shock is the ischemia/reperfusion injury. In this regard, several studies have shown direct activation of complement with a significant increase in MBL and C3 on the endothelium by hypoxic and reperfusion conditions (39). Of note, clinically and experimentally, hemorrhagic shock is a major driver of further organ damage and development of coagulopathy, endotheliopathy, barrier failure, immune dysfunction and MODS after polytrauma (40–43). The close relation of hemorrhagic shock and complement activation reflected by C3 consumption has been previously modeled in baboons where cobra venom factor (CVF) was injected to activate and deplete C3 before a subsequent hemorrhagic shock was induced (20). In pigs, hemorrhagic shock resulted in a drop of CH50 during the hypovolemic phase and also during early resuscitation with enhanced plasma levels of C5a and early detection of endotoxin in the blood, which contributes to MODS (44). A proteomic approach using a rodent hemorrhagic shock model revealed a few alterations of the lymphatic fluid ("toxic lymph"), which included significantly enhanced C3 precursor protein concentrations (45). Since the "toxic lymph" is considered as an
important pathophysiological mechanism in the development of adult respiratory distress syndrome and MODS, these findings indicate C3 as a promising target for immune modulatory approaches (Figure 1).

SEPSIS-INDUCED MODS—ROLE OF COMPLEMENT

Sepsis was long considered as systemic inflammatory response syndrome with evidence of pathogenic microorganisms (46). In contrast, the new definitions describe sepsis rather as organ dysfunction induced by a dysregulated host response to infection (47). This paradigm shift (48) may also change the focus of therapeutic strategies toward support of organ functions, far beyond the established eradication of the pathogens. However, it remains somehow enigmatic what “dysregulation” of the host response means or if the “inadequacy” of the host response is central for development and progression of sepsis.

Multiple experimental sepsis studies have emphasized the detrimental effects of excessive complement activation for the host (Figure 1) (49, 50). This can be considered as a “complement paradox” since complement per se is central to the innate immune defense against invading microorganisms. However, in the context of MODS development caused by sepsis, complement activation seems to enhance rather than protecting against several organ dysfunctions, especially in the heart, lungs and kidneys, representing three central organs in MODS (51–53). The multi-organ gene expression profiles in experimental sepsis seem to be either organ-specific, or common to more than one organ, or distinctly opposite in some organs (54). Furthermore, a balanced pro- and anti-inflammatory genetic response was observed and a differential gene expression for mediators responsible for preventing tissue damage, e.g., protease inhibitors, oxidant neutralizing enzymes, decoy receptors, and proteins which can protect tissue barriers (54). Concerning complement, pre-pro-complement C3 was highly expressed in all organs except in the brain during the whole course of sepsis (54). However, genetic deficiency of C3 resulted in significantly enhanced lethality in comparison to C3-sufficient mice most likely due to a loss of C3b-dependent opsonization of invaded pathogens (55). In contrast, a blockade of C5a by various strategies in sepsis models, e.g., by anti-C5a antibodies, C5aR antibodies, small peptide C5aR1 antagonists, C5a-neutralizing mirror-image (l-)aptamer C5a aptamers, was coherently protective against biochemical and histological evidence of MODS and in general improved survival of sepsis (53, 55–61). All these experimental results demonstrate that C5a-C5aR interaction is clearly involved in the pathogenesis of MODS during sepsis and represents an important therapeutic sepsis target when the novel definitions of sepsis are applied (Figure 1) (47).

In translation to the clinical setting, several non-human primate experiments and studies in humans are in line with the findings in the rodent sepsis model. Evidence of systemic complement activation with reduction of complement hemolytic activity, C3 depletion and enhanced levels of C3a and C5a and corresponding loss of C5aR on neutrophils have been described in several human studies (62–64). Of note, the reduction of C5aR1 and C5aR2 on neutrophils has been correlated with the occurrence of infectious complications in ICU patients (30) and sepsis-induced MODS (62, 65, 66). Since loss of C5aR1 and C5aR2 has been concurrently correlated to the sequential organ failure assessment (SOFA) score (65), a flow-based rapid testing, might have a bedside monitoring potential to predict infectious problems and MODS development.

MODS—PATHOMECHANISMS CAUSED BY MULTIPLE COMPLEMENT DYSFUNCTIONS

Several pathomechanisms contribute to the development of MODS, such as enhanced levels of DAMPs and PAMPs, reduced cytochrome P450 metabolism, macrophage activation syndrome, and cytokine-driven cellular dysfunction (67). Overall, it is clear that complement dysregulation contributes to MODS after trauma (Figure 2). Some of these aspects have been already mentioned and will be further discussed in this section.

Immune Paralysis

Though severely injured patients receive modern ICU management, many of them show signs of immunosuppression known as persistent inflammation-immunosuppressive catabolism syndrome (PICS) (Figure 1) (68). Clinically, PICS patients suffer from persistent inflammation, immune suppression and protein catabolism, which can lead to recurrent nosocomial infections with sepsis, MODS and death (68). Severe immune suppression of the fluid-phase and cellular immune response has been proposed as “immune paralysis” of the host response to sterile and infectious insults. In a clinical case report, an inadequate response to infection with signs of systemic depletion of complement (dropping C3 and C4 levels) has been associated with the development of acute kidney injury and multiple organ failure in a 17-day old newborn (69). C5b-9 and C5a have been described as contributors to cell death, immune paralysis, cardiac dysfunction, and multiple organ failure (Figure 2) (49, 70). In support, a baboon model of Escherichia coli sepsis showed that blockade of C5 protected organs from “immune paralysis” and improved the sepsis survival rate (Table 1) (75).

Dysregulated Complement Regulators

Additional connection between MODS and signs of complementopathy are supported by the fact that soluble and membrane-bound regulators of complement activity show alterations after trauma, sepsis and hemorrhagic shock. It is well-established that severe tissue injury causes an excessive systemic intravascular activation of the complement system resulting in a loss over the control mechanisms (8). In this context, the soluble form of the complement receptor 2 (sCR2) was shown to be present after nerve injury in rodents (80). After polytrauma in humans, leukocyte expression profiles of the complement regulators (CRegs) CD55 (decay accelerating factor), CD59 (membrane attack complex inhibitor), CD46...
Karasu et al. Targeting Complement Pathways in Trauma

![Diagram of MODS pathomechanisms](image)

FIGURE 2 | Complement-mediated pathomechanisms in MODS development. Polytrauma, sepsis and hemorrhagic shock cause a critical complement dysregulation, which causes dysfunction in multiple organs. This figure summarizes potential and known pathomechanisms for MODS development caused by complement dysregulation. Established complement involvement is highlighted in light green and proposed complement involvement is highlighted in gray.

Changes in protease activity
- C5 cleavage
- C5a/C5aR
- pH changes
- Electrophysiological changes C5a

Microcirculatory alterations
- Dysregulation of complement regulators
- Dysregulation of complement regulators sCR2, CD59, CD55, CD46
- C1 inhibitor activity
- Immune paralysis
- C3 & C4 depletion
- C5a, C5b-9, C5aR1

Alteration of Signaling Pathway Activity
Experimental studies showed an interplay of complement with specific signaling pathways including the activation of PKC, MAPKs, and ERK (82). In a non-traumatic renal damage model, NF-κB contributed to enhanced complement activation (83), while in a similar mouse model the C5a/C5aR axis activated MAPK signaling (84). During sepsis, the activation of MAPKs and Akt signaling was complement-induced (51). These mechanistic insights require further elaboration to identify other participating mediators downstream to complement activation in trauma and hemorrhagic shock.

Changes in Protease Activity
Excessive systemic activation of proteases feed in the pathomechanisms of MODS and is known to create a vicious cycle of complement activation. Such proteases include immunoreactive trypsins and neutrophil elastase, which may directly interact with complement and have been extensively described in the case of polytrauma (9). A specific subtype of MODS has been introduced as thrombocytopenia-associated MODS, with low ADAMTS13 activity and defects in inhibitory complement regulators which may result in hyperactivation of coagulation and complement with resultant thrombosis (85). This form of MODS has been successfully treated by C5 blockade (eculizumab) and ADAMTS13 reduction by plasma exchange (67). Furthermore, an unspecific and unregulated protease hyperactivity may directly cleave various complement components in a non-canonical manner, which represents a promising future research field for drug development. In this case, the intestine plays an important role in trauma and during shock, which can proceed to a proposed autodigestion phenomenon, since digestive enzymes from the pancreas are activated by enterokinases (86). Under physiological conditions, the auto-digestion is prevented by epithelial and mucosal barriers. However, during shock digestive peptides can pass the mucus and reach the epithelial cell membranes, where they disrupt junctional complexes, further activate complement and contribute barrier and organ dysfunction (87).

Microcirculatory Alteration
Patients who succumbed to traumatic-hemorrhagic shock showed an impaired microcirculation for at least 72 h, which also was a reliable predictor for a high Sequential Organ Failure Assessment (SOFA) score (88). In an ischemia rat model, application of soluble complement receptor type 1 significantly improved microvascular perfusion in the liver assessed by in vivo microscopy, suggesting an essential role of complement in microcirculatory disorders (89). Activated complement with microvascular alterations can also cause a disruption of cellular barriers leading to edema formation in lung, brain, and liver (84, 90, 91). However, hypothetical complement-caused damage of specific tight junction molecules in specific organs needs still scientific verification. Such mechanisms of MODS development may also be supported by simultaneous activation of complement and coagulation e.g., by complement-dependent generation of thrombin, which is known to efficiently break down various endothelial barriers. Furthermore, complement hyperactivation has been associated with thrombotic microangiopathies causing...
TABLE 1 | Most representative preclinical studies addressing trauma, HS and sepsis, respectively.

| Model | Intervention | Outcome | References |
|-------|--------------|---------|------------|
| Trauma | Mouse TBI | CR2-fH: C3 deposition Inhibition | Less C3 deposition in brain; decreased microglia activation; less neuronal cell death | (71) |
| Mouse TBI | C6 antisense oligonucleotide Inhibition of MAC formation Coversin (OMCÎ) C5 inhibition | Inhibition of C6: less cerebral MAC (up to 96%); inhibition of C6 synthesis (> 80%) | (72) |
| Mouse TBI | CD59-2a-CRIg Terminal pathway (MAC) inhibition | Less axonal damage; enhanced neurological recovery; inhibition of C5: decreased MAC formation; improved neurological outcome | (73) |
| Mouse TBI | CR2-CD59: Terminal pathway (MAC) inhibition | | |
| | CR2-Crry: all complement pathways inhibition | CR2-fH: alternative complement pathway inhibition | |
| | RA101295: C5 inhibition | Significantly improved survival; reduced inflammation and coagulopathy; significantly improved organ function | (75) |
| Sepsis | Baboon septic shock | PMX 205: C5ar antagonist | Protection from invasive meningococcal infection; enhanced mouse survival; ameliorated inflammatory cytokine response | (76) |
| | Piglets poly-microbial sepsis | Coversin (OMCÎ) C5 inhibition And Anti-CD14 | Combined C5 and CD14 inhibition: significantly improved survival; significantly lower plasma sC5b-9 levels, which correlated with mortality | (77) |
| | Baboon septic shock | Comstatin: C3 inhibition | Significantly decreased procoagulant response; organ protection by significantly improved vascular barrier function; less leukocyte infiltration and cell death | (5) |
| HS | NHP HS | Comstatin C3 blockade | Protection of organ function; reduced intestinal edema; improved kidney function | (78) |
| Swine trauma with HS | C1 inhibition | | |

HS, hemorrhagic shock; MAC, membrane attack complex; NHP, non-human primate; TBI, traumatic brain injury; TNF, tumor necrosis factor.

endothelial cell activation and thrombus formation leading to hemolytic anemia, thrombocytopenia, and organ failure (91).

Metabolic Changes
Besides microcirculatory problems, massive blood loss due to hemorrhage can cause acute circulatory failure resulting in lactic acidosis. Acute liver or renal dysfunctions are most often associated with decreased lactate clearance and a pronounced increase in blood lactate levels compared with shock patients without signs of liver or renal dysfunction (92). It is also known that shock states initiate a pronounced compensatory vasoconstriction, consequently leading to hypoxia and accumulation of metabolites associated with lactate acidosis and a low pH milieu (92, 93). In this context, complement dysfunction has a deleterious influence and correlates with a worse outcome after shock. Especially the anaphylatoxin C5a and its following signaling via the C5aR1 have been described to further enhance acidosis after septic shock. More precisely, in vitro stimulation of neutrophils from healthy donors with C5a causes C5aR1 signaling-mediated immunometabolic changes in neutrophils with an enhanced glucose uptake and enhanced glycolytic flux (Figure 2) (94). In turn, it can initiate an increased proton secretion and further lower the extracellular pH. In response to C5a exposure, intracellular pH in neutrophils significantly increases via activation of the Na+⁄H+ exchanger type 1 (NHE-1) leading to an impairment in neutrophil function in vitro. Supporting this evidence, neutrophils isolated from septic patients has been shown to exhibit an increased intracellular pH compared to healthy donors (94). These recent findings indicate that inflammatory processes with produced C5a is solely capable to significantly change the micro-milieu with lactate acidotic features even in the absence of an oxygen deficit. It only can be speculated on, that in the case of an additional oxygen deficit, caused by shock conditions and vascular dysfunction, the anaphylatoxins may even function as a metabolic switch toward lactate acidosis and MODS.

Microbiome Alterations
The intestinal complement is suggested to cooperate in a close relationship with the gut microbiome (95). Therefore, another
contributor to MODS seems to be the alteration of the gut microbiome after trauma/hemorrhagic shock and/or sepsis. The microbiome, which is described by the phylogenetic composition and taxon relative abundance of the bacteria, is significantly altered in the first 72h after injury. This rapid change in intestinal microbiota represents a critical phenomenon that may influence outcomes after severe trauma (15). The composition of the microbiome may influence the activation/dysregulation of complement pathways or dysregulated complement may change the microbiome composition. In the skin, complement activation modulates the inflammatory milieu by changing the cutaneous microbiota (96). Considering MODS, a mechanistic explanation for complement-microbiome interaction still remains elusive and needs further research.

**Alterations in Microvesicle (MV) Shedding**
Communication is essential for cellular homeostasis and vesicle shedding has been described to play a crucial role for maintaining proper immune cell function. Extracellular vesicle shedding has been described to play a crucial role for maintaining communication. Alterations in Microvesicle (MV) Shedding for complement pathways or dysregulated complement may change the microbiome composition. In the skin, complement activation modulates the inflammatory milieu by changing the cutaneous microbiota (96). Considering MODS, a mechanistic explanation for complement-microbiome interaction still remains elusive and needs further research.

**TARGETING COMPLEMENT PATHWAYS IN MODS**

Despite improvements in trauma care, the morbidity and mortality of MODS remains very high. Therefore, new therapeutic strategies are urgently needed. Since complement is critically involved in initiation and progression of MODS, targeting complement as well as molecules contributing to complement activation represent promising future clinical approaches. Other complement-associated inflammatory conditions already addressed such a targeting strategy. Above 20 complement-interfering drugs have been evaluated in clinical settings so far. A few of them received FDA approval for inflammatory indications including eculizumab targeting the terminal complement pathway starting from C5, which is currently used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) (103). As existing complement therapeutics cannot target every complement-driven disease status, it is a requisite to evaluate the different complement stages, their relevance, and target them in a disease-specific manner (10).

In the context of trauma, hemorrhagic shock and sepsis a few preclinical experimental studies focus on complement-targeting studies (Table 1). Besides complement activation products, other molecules including CRP, HMGB1, or mitochondrial DNA play crucial roles in contributing to complement dysregulation after sepsis and trauma, thus profoundly influencing secondary outcomes. Therefore, a rational approach seems to address molecules, which may further boost complement activity. Likewise, HMGB1 is a relevant danger molecule and complement...
has been described to regulate HMGB1 release from human neutrophils (104) such that, complement inhibition has proved to be protective in blast-induced acute lung injury in rats by ameliorating HMGB1-mediated inflammation (105).

**Targeting Complement After (poly)Trauma**

In polytrauma patients, the only study of complement intervention early after trauma with RCT quality used C1 esterase inhibitor. However, this study has been terminated based on the heterogeneity of the patients (106). Experimentally, the majority of the complement targeting studies were performed in mouse traumatic brain injury (TBI) models. In this case, various interventions to inhibit complement activity, such as inhibitors for MAC formation and C3 deposition inhibitors have been applied, analyzed and reviewed elsewhere (9, 107, 108). To further clarify the impact of distinct complement activation pathways on neuroinflammation, a recent study compared the effect of complement inhibitors targeting upstream as well as downstream complement activity, respectively. This study brought into light that instead of downstream complement activation complexes, upstream complement activation products of the alternative pathway predominantly modulate and propagate chronic inflammation (74) (Table 1).

**Targeting Complement in Hemorrhagic Shock**

Based on the deduced potential of complement inhibitors to improve micro-perfusion disturbances, ischemia/reperfusion injury and the inflammatory response during hemorrhagic shock, various shock models have been tested for possible benefits of complement interventions. In a rat model of pressure controlled hemorrhagic shock, complement depletion by CVF improved the recovery of the mean arterial pressure (MAP) post shock (109). In a pig model of pressure controlled hemorrhagic shock, application of a C1-inhibitor improved the functional performance and reduced C3 deposition on a multi-organ level including liver, small intestine and lungs (Table 1) (79). Limitation of organ injury and sustained survival by C1 inhibitor therapy has also been reported for a porcine injury model mimicking battlefield injury (110). Further downstream, C3 deficient mice with bilateral femur fracture and hemorrhagic shock resulted in protective effects with reduced circulating DAMPs (e.g., dsDNA), decreased systemic inflammatory response and improved organ performance (e.g., liver enzymes) (111). In a rat model of hemorrhagic shock, C3 depletion by CVF, and the soluble form of CR1 to inhibit C3 action restored vascular reactivity to norepinephrine in the superior mesenteric artery (112). In the clinical setting, C3 inhibition has not been tested in hemorrhagic shock so far except in a recent study from our group, where non-human primates were modeled with severe hemorrhagic shock of 30 mmHg MAP for 1 h, and a delayed application of CP40 was tested (78). C3 blockade by the compstatin compound CP40 seems most promising since there was evidence of improved renal function, attenuated intestinal edema and reduced signs of systemic inflammation and coagulopathy (78). However, the transfer into clinical reality is pending although C3 inhibition seems rather safe in the case of hemorrhagic shock. Most likely, an early inhibition to avoid excessive C3 activation might be enough to improve the outcome (113).

On a C5 level, intestinal injury caused by hypovolemic shock in mice was ameliorated by application of a small peptide C5aR1 antagonist and C5 deficient littermates (114). Similarly, in a rodent model of ruptured aortic abdominal aneurysma with shock, C5 blockade by an anti-C5 antibody revealed some protective effects on remote lung injury with improvement of the bronchoalveolar permeability and myeloperoxidase (MPO) concentrations reflecting reduced neutrophil recruitment and activation (115). Combined inhibition of the complement component C5 and the Toll-like receptor co-factor CD14 in a porcine sepsis model, showed beneficial effects in regard to survival, hemodynamic parameters and systemic inflammation including complement activation (Figure 1, Table 1). First preclinical studies in non-human primates indicate appearance of sC5b-9 in the serum of traumatic-hemorrhagic shock and ex vivo effectiveness of C5 inhibitors in prevention of hemolysis, e.g., the small, inhibitory peptide RA101348, commercially-available C5 inhibitory antibodies and Quidel’s A217 antibody (106). However, a RCT-clinical study with C5 inhibitory strategies in hemorrhagic shock has not been performed so far most likely based on the rareness and uncertain evidence of a great impact on MODS development in the so far performed preclinical non-human primate studies. Therefore, research providing information about the histological and biochemical data on the multi-organ level in non-human primate studies is necessary for final assessment.

**Targeting Complement in Sepsis**

In the case of septic shock, targeting the C5a/C5aR axis seems to be of practical importance since it correlated with the disease severity and mortality and showed promising improvements in different sepsis models (Table 1). Concerning complement-targeted therapies in sepsis, application of RA101295, a 2-kDa macrocyclic peptide inhibitor of C5 cleavage, improved organ performance and survival in an E. coli-sepsis model of baboons (75) with lessened evidence of coagulopathy and preserved endothelial and barrier functions. Furthermore, the inhibition of C5 cleavage lead to improved histomorphology of lungs, liver, kidneys, spleen, and adrenal glands suggesting improvement of sepsis-induced MODS (75).

In the same sepsis model, systemic blockade of C3 by compstatin also revealed organ protection on multiple levels. Compstatin showed evidence of sepsis-induced coagulopathy and preserved anti-coagulatory features of the endothelium. Furthermore, C3 blockade improved hemodynamics and heart function and biochemical damage markers of the kidney and liver, indicating protective effects in sepsis-induced MODS (5). For blocking the central complement component C3 during development of sepsis-caused MODS, clinical trials might be safe (113) but these trials are pending and require a special focus on the benefits or maladies for mental alterations during sepsis.

In terms of applicability in the clinical setting, it has been recently shown that blocking solely C5 activation by canonical C5-convertase (e.g., by eculizumab) might not be specific enough...
since other serine proteases such as trypsin or thrombin can still cleave and activate C5. Therefore, a C5a blocking approach e.g., by IFX-1 anti-C5a antibody has been proposed as a targeted approach in local or systemic infection (e.g., by IFX-1 anti-C5a antibody has been proposed as a targeted approach in local or systemic infection (116, 117). Overall, the specific complement targets for sepsis-induced MODS might be different than for polytrauma- or hemorrhagic shock-caused MODS especially when given early (Figure 1). The complement target might also change along the course of the disease. It is for example feasible, that early after polytrauma or during hemorrhagic shock a specific C3 inhibition is required, whereas later during development of septic complications, C5a inhibition might help against MODS development (Figure 1). And if complete depletion of a specific complement factor occurs, it might be even wise to replace it, which bolsters the importance of monitoring complement for any clinical trial.

In conclusion, MODS is a culmination of highly heterogeneous events which can involve different and complex stages of complement activation, making it nearly impossible to generate a drug addressing MODS generally. More precisely, the most prominent complement pathways and their down-stream signaling pathways involving multiple trauma with or without hemorrhagic shock and septic shock may be addressed in further preclinical studies.

Clinical Trials
Considering clinical trials of MODS caused by polytrauma, hemorrhagic shock and sepsis, three observational studies addressed complement activation after polytrauma and severe abdominal sepsis (Table 2). One study focused on the complement activation and expression on leukocytes in polytrauma patients revealing increased complement activity early after trauma and an increased shedding of complement receptors from neutrophil surfaces (NCT00710411; Table 2) (2, 62). Another observational study focuses on the molecular danger response after polytrauma. It is still recruiting patients, and the study aims to include up to 1,000 patients in a collective national data bank in collaboration with the Trauma Research Network (NTF) of the German Society for Orthopedics and Trauma (DGOU) and thus to obtain novel insight into the molecular pattern of complement activity following severe multiple injury (NTF-PT; NCT02682550; Table 2).

A further observational study has set its focus on the central complement C3 by investigation of C3 alterations in patients with severe abdominal sepsis. The aim was to evaluate the impact of C3 on patients’ prognosis (NCT01568853; Table 2). This study revealed that C3 depletion is associated with a poor prognosis due to dysregulated coagulation and increased susceptibility for infections (118).

In regard to human studies, three interventional trials have been initiated so far (Table 3). One study addressed the inhibition of upstream complement component (C1) by targeting C1 esterase. This mono-centered double-blind randomized placebo-controlled trial (CAESAR; NCT01275976, Table 3) has been designed using a C1-esterase inhibitor in severely injured patients.
with femur fracture. Although the rationale of a complement blockade on this level is very well founded because it may also reveal beneficial effects by synchronously inhibition of excessive activation of the coagulation pathway (119), the study has been terminated based on the heterogeneity of patients and challenges in recruitment. A further study has addressed the effect of the C1-esterase inhibitor on human endotoxemia by evaluating its effect on inflammation and marker of organ dysfunction (VECTOR; NCT00785018, Table 3). Detailed results of the study are still pending.

Another clinical trial has been designed and performed to study complement inhibition in early, newly developing septic organ dysfunction (SCIENCE; NCT02246595, Table 3) applying a monoclonal antibody against C5a, though the detailed results of this trial have not been published so far. Regarding one cardinal clinical sign of sepsis, the occult or evident alterations of the mental status, inhibitory strategies against C5a might reveal “Janus faced” effects (120). On one hand, C5a inhibition could improve sepsis-impaired blood-brain-barrier, on the other hand, neuroprotective effects by C5a might be compromised (120, 121). Therefore, alterations of the mental status need to be carefully addressed and monitored in any clinical trial using C5a inhibitory strategies.

It is important to note, that it is in general rather difficult to perform interventional studies on polytrauma patients since an informed written consent cannot be provided and the legal representatives are usually difficult to determine within the first hours after severe injury. Therefore, innovative studies early after polytrauma addressing the complement cascade are rather rare and have not been performed on the C3 or C5 level yet.

**CLINICAL PERSPECTIVES**

Although various clinically relevant models of trauma, hemorrhagic shock and sepsis have been tested already in non-human primates for the benefit of complement interventions (75, 78, 106), clinical trials in these multidimensional pathophysiologic conditions remain rare (119, 122). When complement intervention strategies are designed for the clinics, the targeted complement factor or activation product needs to be measured before the therapy can be applied. Especially when complex intensive care is necessary which can alter complement levels within a short time period, e.g., by infusion of blood products which contain highly variable concentrations of complement (activation) factors (123) or by extra-corporeal circulation devices with large artificial surfaces which may deplete key complement components (124, 125), the exact status of complement activation needs to be determined. This would allow precise and timely intervention either by inhibiting or supporting the complement response after trauma or during sepsis in order to rebalance the immune response. Whereas, various highly effective and specific complement intervention strategies have been developed within the last two decades and are available now (10), in the context of the complex immune response after trauma, hemorrhagic shock and sepsis (9, 126), specific organ damage and function assessment including the immune function at bedside seems far beyond. Therefore, functional monitoring of the organ and immune systems can be considered as a prerequisite before complement interventions move into clinical routine in diseases with a complex pathophysiology. In conclusion, further scientific knowledge and translational efforts are demanded for targeting complement pathways in the setting of trauma, hemorrhagic shock and sepsis with the aim to offer causal therapy and improved outcome.

**AUTHOR CONTRIBUTIONS**

EK and MH-L wrote the manuscript. All authors edited and commented on the manuscript. All authors read and approved the final manuscript.

**FUNDING**

This review was supported by grants from the German Research Foundation (DFG) (EI 866/5-1) and by grants from the DFG within the Collaborative Research Center CRC1149/2 Danger Response, Disturbance Factors and Regenerative Potential after Acute Trauma to MH-L.
11. Cavaillon JM, Annane D. Compartmentalization of the inflammatory response in sepsis and SIRS. J Endotoxin Res. (2006) 12:151–70. doi: 10.1179/096805106X102246

12. Cavaillon JM, Giamarellos-Bourboulis EJ. < Immunosuppression > is inappropriately qualifying the immune status of septic and sirs patients. Crit Care Med. (2018) 46:733–34. doi: 10.1097/CCM.0000000000003225

13. Riedemann NC, Guo RF, Neff TA, Laudes IJ, Keller KA, Sarma VJ, et al. Increased C5a receptor expression in sepsis. J Clin Invest. (2002) 110:101–8. doi: 10.1172/JCI215409

14. Messerer DAC, Denk S, Fohr KJ, Halbgabeuer R, Braun CK, Hones F, et al. Complement C5a alters the membrane potential of neutrophils during hemorrhagic shock. Mediators Inflamm. (2018) 2018:2052356. doi: 10.1155/2018/2052356

15. Howard BM, Kornblith LZ, Christie SA, Conroy AS, Nelson MF, Campion ME, et al. Characterizing the gut microbiome in trauma: significant changes in microbial diversity occur early after severe injury. Trauma Surg Acute Care Open. (2017) 2:e000108. doi: 10.1136/tsaco-2017-000108

16. Graetz TJ, Hotchkiss RS. Sepsis: preventing organ failure in sepsis – the search continues. Nat Rev Nephrol. (2013) 12:135–40. doi: 10.1038/nrneph.2017.171

17. Coopersmith CM, De BD, Deutschman CS, Ferrer R, Lat I, Machado FR, et al. Surviving sepsis campaign: research priorities for sepsis and septic shock. Crit Care Med. (2018) 46:1334–56. doi: 10.1097/CCM.0000000000003325

18. Chakraborty S, Karasu E, Huber-Lang M. Complement after trauma: sputtering innate and adaptive immunity. Front Immunol. (2018) 9:2050. doi: 10.3389/fimmu.2018.02050

19. van Wessem KJP, Leenen LPH. Reduction in mortality rates of postinjury multiple organ dysfunction syndrome: a shifting paradigm? a prospective population-based cohort study. Shock. (2018) 49:33–8. doi: 10.1097/SHK.0000000000000938

20. Roumen RM, Redh H, Schlag G, Zilow G, Sandtner W, Koller W, et al. Inflammatory mediators in relation to the development of multiple organ failure in patients after severe blunt trauma. Crit Care Med. (1995) 23:474–80. doi: 10.1097/00003246-199503000-00010

21. Baustch W, Hoymann HG, Zhang Q, Meier-Wiedenbach I, Raschke U, Ames RS, et al. Cutting edge: guinea pigs with a natural C3a-receptor defect exhibit decreased bronchoconstriction in allergic airway disease: evidence for an involvement of the C3a anaphylatoxin in the pathogenesis of asthma. J Immunol. (2000) 165:5401–5. doi: 10.4049/jimmunol.165.10.5401

22. Asgari E, Le FG, Yamamoto H, Perucha E, Sacks SS, Kohl J, et al. C3a modulates IL-1beta secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood. (2013) 122:3473–81. doi: 10.1182/blood-2013-05-502229

23. Ehrnthaller C, Flierl M, Perl M, Denk S, Unnewehr H, Ward PA, et al. An integrated clinico-transcriptomics approach identifies a central role of the heme degradation pathway for septic complications after trauma. Ann Surg. (2016) 264:1125–34. doi: 10.1097/SLA.0000000000001553

24. Abdelbaset-Ismail A, Borkowska-Rzeszotek S, Kubis E, Bujko K, Brezniakiewicz-Isman J, Kollun L, et al. Activation of the complement cascade enhances motility of leukemic cells by downregulating expression of HO-1. Leukemia. (2017) 31:446–58. doi: 10.1038/leu.2016.198

25. May O, Merle NS, Grunenwald A, Gnemmi V, Leon J, Payet C, et al. Endothelial glycocalyx shedding and vascular permeability in severely injured trauma patients. J Transl Med. (2015) 13:50. doi: 10.1186/s12967-015-0481-5

26. May O, Merle NS, Grunenwald A, Gnemmi V, Leon J, Payet C, et al. Hemorrhagic shock drives glycocalyx, barrier and organ dysfunction after polytrauma and hemorrhagic shock. Shock. (2018). doi: 10.1097/SHK.0000000000001271. [Epub ahead of print].

27. Rittirsch D, Schoenborn V, Lindig S, Sanner E, Sprengel K, Gunkel S, et al. An integrated clinico-transcriptomic approach identifies a central role of the heme degradation pathway for septic complications after trauma. Ann Surg. (2016) 264:1125–34. doi: 10.1097/SLA.0000000000001553

28. Noris M, Remuzzi G. Overview of complement activation and regulation. Semin Nephrol. (2013) 33:479–92. doi: 10.1016/j.semnephrol.2013.08.001

29. Amara U, Kaltbuz M, Perl M, Flierl MA, Rittirsch D, Weiss M, et al. Early expression changes of complement regulatory proteins and C5a receptor. (CD88) on leukocytes after multiple injury in humans. Shock. (2010) 33:568–75. doi: 10.1097/SHK.0b013e3181e799d4

30. Morris AC, Brittan M, Wilkinson TS, McAuley DF, Antonelli J, McCulloch C, et al. C5a-mediated neutrophil dysfunction is Rhoades-dependent and predicts infection in critically ill patients. Blood. (2011) 117:5178–88. doi: 10.1182/blood-2010-08-304660

31. Morganroth ML, Schoeneich SO, Tal GO, Ward PA, Horvath SJ, Glovsky MM, et al. C3a57–77, a C-terminus peptide, causes thrombomodulin-dependent pulmonary vascular constriction in isolated perfused rat lungs. Am Rev Respir Dis. (1990) 141:296–300. doi: 10.1164/ajrccm.141.2.296

32. Crowell RE, Van Epps DE, Reed WP. Responses of isolated pulmonary artery: further evidence for leukocyte-dependent vasoemotion. J Cardiovasc Pharmacol. (2002) 40:815–21. doi: 10.1097/00005344-200212000-00002

33. Fortin JP, Bouthillier J, St-Pierre SA, Marceau F. Contractile effect of anaphylatoxin C5a and of a mimetic peptide on the human umbilical artery: further evidence for leukocyte-dependent vasoemotion. J Cardiovasc Pharmacol. (2002) 40:815–21. doi: 10.1097/00005344-200212000-00002

34. Guilbins E, Schlotmann K, Rauterberg EW, Steinhausen M. Effects of c5a on the circulation of normal and split hydroncrotic rat kidneys. Am J Physiol. (1993) 265(1 Pt 2):F96–103. doi: 10.1152/ajprenal.1993.265.1.F96

35. Lundberg C, Marceau F, Hugli TE. C5a-induced hemodynamic and hematologic changes in the rabbit. Role of cyclooxygenase products and polymorphonuclear leukocytes. J Pathol. (1987) 128:471–83.

36. Rendig SV, Gray S, Amsterdam EA. Contractile actions of C5a on isolated porcine coronary resistance and conductance arteries. Am J Physiol. (1997) 272(1 Pt 2):H12–6. doi: 10.1152/ajpheart.1997.272.1.H12

37. Schumacher WA, Fantone JC, Kinkel SE, Webb RC, Lucchesi BR. The anaphylatoxins C3a and C5a are vaso-dilators in the canine coronary vasculature in vitro and in vivo. Agents Actions. (1991) 34:345–9. doi: 10.1007/BF01988727

38. Marceau F, Hugli TE. Effect of C5a and C5a anaphylatoxins on guinea-pig isolated blood vessels. J Pharmacol Exp Ther. (1984) 230:749–54. doi: 10.1124/jpet.309.1.1600195

39. Halbgabeuer R, Braun CK, Denk S, Mayer B, Cinelli P, Radermacher P, et al. Hemorrhagic shock drives glycolysis, barrier and organ dysfunction after polytrauma and hemorrhagic shock. Shock. (2018). doi: 10.1097/SHK.0000000000001271. [Epub ahead of print].
Karasu et al. Targeting Complement Pathways in Trauma

48. Dickmann P, Scherag A, Coldewey SM, Sponholz C, Brunhhorst FM, Bauer M. [Epistemology in the intensive care unit—what is the purpose of a definition?]: paradigm shift in sepsis research. Anaesthesis. (2017) 66:622–5. doi: 10.1007/s00101-017-0315-3

49. Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol. (2004) 4:133–42. doi: 10.1038/nri1269

50. Gerard C. Complement C5a in the sepsis syndrome—too much of a good thing? N Engl J Med. (2003) 348:167–9. doi: 10.1056/NEJMcb022295

51. Fattahi F, Kalbitz M, Malan EA, Abe E, Jajou L, Huber-Lang MS et al. Complement-induced activation of MAPKs and Akt during sepsis: role in cardiac dysfunction. FASEB J. (2017) 31:4129–39. doi: 10.1096/fj.201700140R

52. Mira JC, Brakenridge SC, Moldawer LL, Moore FA. Persistent inflammation, immunosuppression and cachexia syndrome. Crit Care Clin. (2017) 33:245–58. doi: 10.1016/j.ccc.2016.12.001

53. Rittirsch D, Tremblay MM, Litalien C, Patey N, Merouani A. Severe acute kidney injury and multiple organ failure in a 17-day-old newborn: when pathology makes the difference. Can J Kidney Health Dis. (2018) 5:205438118804834. doi: 10.10771/205438118804834

54. Liao JW, Chien YS, Lin YJ, et al. Combined inhibition of complement and CD14 improved treatment. Circulation. (2018) 138:2519–2532. doi: 10.1161/CIRCULATIONAHA.117.027863

55. Mollnes TE, Male R, Rittirsch D, Nadeau BA, Day DE, Sarma JV, et al. The complement anaphylatoxin C5a induces apoptosis in adrenomedullary cells during experimental sepsis. PLoS ONE. (2008) 3:e2560. doi: 10.1371/journal.pone.0002560

56. Fattahi F, Kalbitz M, Herron TJ, Grailer JI, Jajou L, Huber-Lang MS et al. Changes and regulation of the C5a receptor on neutrophils in vivo after polymicrobial sepsis and in vitro. J Immunol. (2016) 197:2353–61. doi: 10.4049/jimmunol.1600049

57. Fabry G, Mollergaard C, Moller C, et al. Changes in the novel orphan, C5a receptor (C5L2), during sepsis: role in cardiac dysfunction. FASEB J. (2018) 32:13555. doi: 10.1096/fj.2017026124

58. Lauder B, Mollergaard C, Moller C, et al. Protection of innate immunity by C5AR antagonist in septic mice. J Immunol. (2002) 169:1569–74. doi: 10.4049/jimmunol.02-0209com

59. Lindblom RP, Aeinehband S, Strom M, Al NF, Sandholm K, Khademi M, et al. Combined inhibition of complement and CD14 improved outcome in porcine polymicrobial sepsis. Crit Care. (2015) 19:4145. doi: 10.1186/s13054-015-1129-9

60. van GM, Rittirsch D, Bautsch W, et al. Protective effects of complement C5a receptor 1 exacerbates the pathophysiology of N. meningitidis sepsis and is a potential target for disease treatment. MBio. (2018) 9(1). doi: 10.1128/mBio.01755-17

61. Podd B, Aneja R, Weiss SL, Hall MW, Cornell TT, et al. Pathophysiology of pediatric multiorgan dysfunction syndrome. Pediatr Crit Care Med. (2017) 18(3 Suppl. 1):S32–45. doi: 10.1097/PPCC.0000000000001052

62. Mira JC, Brakenridge SC, Moldawer LL, Moore FA. Persistent inflammation, immunosuppression and cachexia syndrome. Crit Care Clin. (2017) 33:245–58. doi: 10.1016/j.ccc.2016.12.001

63. Gaudreault-Tremblay MM, Litalien C, Patey N, Merouani A. Severe acute kidney injury and multiple organ failure in a 17-day-old newborn: when pathology makes the difference. Can J Kidney Health Dis. (2018) 5:205438118804834. doi: 10.10771/205438118804834

64. Reuseva MM, Ramaglia V, Morgan BP, Harris CL. An anticomplement agent that homes to the damaged brain and promotes recovery after traumatic brain injury in mice. J Immunol. (2014) 192:2339–48. doi: 10.4049/jimmunol.1302793

65. van GM, Rittirsch D, Bautsch W, et al. Protective effects of complement C5a receptor 1 exacerbates the pathophysiology of N. meningitidis sepsis and is a potential target for disease treatment. MBio. (2018) 9(1). doi: 10.1128/mBio.01755-17

66. Lauder B, Mollergaard C, Moller C, et al. Protection of innate immunity by C5AR antagonist in septic mice. J Immunol. (2002) 169:1569–74. doi: 10.4049/jimmunol.02-0209com

67. Fattahi F, Kalbitz M, Herron TJ, Grailer JI, Jajou L, Huber-Lang MS et al. Changes and regulation of the C5a receptor on neutrophils during septic shock in humans. J Immunol. (2013) 190:4215–25. doi: 10.4049/jimmunol.1200534

68. Mira JC, Brakenridge SC, Moldawer LL, Moore FA. Persistent inflammation, immunosuppression and cachexia syndrome. Crit Care Clin. (2017) 33:245–58. doi: 10.1016/j.ccc.2016.12.001

69. Gaudreault-Tremblay MM, Litalien C, Patey N, Merouani A. Severe acute kidney injury and multiple organ failure in a 17-day-old newborn: when pathology makes the difference. Can J Kidney Health Dis. (2018) 5:205438118804834. doi: 10.10771/205438118804834

70. Mira JC, Brakenridge SC, Moldawer LL, Moore FA. Persistent inflammation, immunosuppression and cachexia syndrome. Crit Care Clin. (2017) 33:245–58. doi: 10.1016/j.ccc.2016.12.001

71. Carcillo JA, Podd B, Aneja R, Weiss SL, Hall MW, Cornell TT, et al. Pathophysiology of pediatric multiorgan dysfunction syndrome. Pediatr Crit Care Med. (2017) 18(3 Suppl. 1):S32–45. doi: 10.1097/PPCC.0000000000001052

72. Mira JC, Brakenridge SC, Moldawer LL, Moore FA. Persistent inflammation, immunosuppression and cachexia syndrome. Crit Care Clin. (2017) 33:245–58. doi: 10.1016/j.ccc.2016.12.001

73. Carcillo JA, Podd B, Aneja R, Weiss SL, Hall MW, Cornell TT, et al. Pathophysiology of pediatric multiorgan dysfunction syndrome. Pediatr Crit Care Med. (2017) 18(3 Suppl. 1):S32–45. doi: 10.1097/PPCC.0000000000001052

74. Carcillo JA, Podd B, Aneja R, Weiss SL, Hall MW, Cornell TT, et al. Pathophysiology of pediatric multiorgan dysfunction syndrome. Pediatr Crit Care Med. (2017) 18(3 Suppl. 1):S32–45. doi: 10.1097/PPCC.0000000000001052

75. Carcillo JA, Podd B, Aneja R, Weiss SL, Hall MW, Cornell TT, et al. Pathophysiology of pediatric multiorgan dysfunction syndrome. Pediatr Crit Care Med. (2017) 18(3 Suppl. 1):S32–45. doi: 10.1097/PPCC.0000000000001052

76. Carcillo JA, Podd B, Aneja R, Weiss SL, Hall MW, Cornell TT, et al. Pathophysiology of pediatric multiorgan dysfunction syndrome. Pediatr Crit Care Med. (2017) 18(3 Suppl. 1):S32–45. doi: 10.1097/PPCC.0000000000001052

77. Carcillo JA, Podd B, Aneja R, Weiss SL, Hall MW, Cornell TT, et al. Pathophysiology of pediatric multiorgan dysfunction syndrome. Pediatr Crit Care Med. (2017) 18(3 Suppl. 1):S32–45. doi: 10.1097/PPCC.0000000000001052
Karasu et al. Targeting Complement Pathways in Trauma

of subarachnoid hemorrhage. Acta Neurochir Suppl. (2013) 118:157–61. doi: 10.1007/978-3-7091-1434-6_29

85. Nguyen TC, Cruz MA, Carcillo JA. Thrombocytopenia-associated multiple organ failure and acute kidney injury. Crit Care Clin. (2015) 31:661–74. doi: 10.1016/j.ccc.2015.06.004

86. DeLang FA, Hoyt DB, Schmid-Schonbein GW. Pancreatic digestive enzyme blockade in the intestine increases survival after experimental shock. Sci Transl Med. (2013) 5:169ra11. doi: 10.1126/scitranslmed.3005046

87. Schmid-Schonbein GW. 2008 Landsis award lecture. Inflammation and the autodigestion hypothesis. Microcirculation. (2009) 16:289–306. doi: 10.1080/10739680902801949

88. Tachon G, Harrois A, Tanaka S, Kato H, Huet O, Pottecher J, et al. Microcirculatory alterations in traumatic hemorrhagic shock. Crit Care Med. (2014) 42:1433–41. doi: 10.1097/CCM.0000000000000223

89. Lehmann TG, Koeppl TA, Munch S, Heger M, Kirschfink M, Klar E, et al. Impact of inhibition of complement by sCR1 on hepatic microcirculation after warm ischemia. Microvasc Res. (2001) 62:284–92. doi: 10.1016/S0026-2862(01)20074-7

90. Nuytinck JK, Goris RJ, Weerts JG, Schillings PH, Stekhoven JH. Acute complement-mediated thrombotic microangiopathies. Microvasc Res. (2001) 62:284–92. doi: 10.1016/S0026-2862(01)20074-7

91. Karasu E, Eisenhardt SU, Harant J, Huber-Lang M. Extracellular vesicles in paroxysmal nocturnal hemoglobinuria. Oncologist. (2008) 13:993–1000. doi: 10.1634/theoncologist.2008-0086

92. Wang C, Wang H, Chang DY, Hao J, Zhao MH, Chen M. High mobility group box 1 contributes to anti-neutrophil cytoplasmic antibody-induced neutrophils activation through receptor for advanced glycation end products (RAGE) and Toll Like receptor 4. Arthritis Res Ther. (2015) 17:46. doi: 10.1186/s13075-015-0587-4

93. Li Y, Yang Z, Chavko M, Liu B, Aderemi OA, Simovic MO, et al. Complement inhibition ameliorates blast-induced acute lung injury in rats: potential role of complement in intracellular HMGB1-mediated inflammation. PLoS ONE. (2013) 8:e202594. doi: 10.1371/journal.pone.02594

94. Paredes RM, Reyna S, Nopporn P, Dallatuka JJ, Shreffard F. Generation of complement molecular complex C5b-9 (C5b-9) in response to poly-traumatic hemorrhagic shock and evaluation of C5 cleavage inhibitors in non-human primates. Int Immunopharmacol. (2018) 54:221–5. doi: 10.1016/j.intimp.2017.10.033

95. Roselli E, Karasu E, Volpe C, Huber-Lang M. Medusa’s head: the complement system in traumatic brain and spinal cord injury. J Neuotrauma. (2018) 35:226–40. doi: 10.1089/neu.2017.5168

96. Hammad A, Westacott L, Zaben M. The role of the complement system in traumatic brain injury: a review. J Neuroinflammation. (2015) 12:24. doi: 10.4161/temp.29761

97. Campbell JC, Li Y, van AE, Relan A, Dubick M, Shreffard F, et al. C1 Inhibitor limits organ injury and prolongs survival in swine subjected to battlefield simulated injury. Shock. (2016) 46(3 Suppl. 1): 177–88. doi: 10.1097/SHK.0000000000000677

98. Cai C, Gill R, Eum HA, Cao Z, Loughran PA, Darwiche S, et al. Complement factor 3 deficiency attenuates hemorrhagic shock-related hepatic injury and systemic inflammatory response syndrome. Am J Physiol Regul Integr Comp Physiol. (2010) 299:R1175–82. doi: 10.1152/ajpregu.00282.2010

99. Chen D, Song MQ, Liu YJ, Xue YK, Cheng P, Zheng H, et al. Inhibition of complement C3 might rescue vascular hyporeactivity in a conscious hemorrhagic shock rat model. Microvasc Res. (2016) 105:23–9. doi: 10.1016/j.mvr.2015.12.006

100. Reis ES, Berger N, Wang X, Koutsogiannaki S, Doot RK, Gumas JT, et al. Safety profile after prolonged C3 inhibition. Clin Immunol. (2018) 197:96–106. doi: 10.1016/j.clim.2018.09.004

101. Fleming SD, Phillips LM, Lambiris JD, Tsokos GC. Complement component C5a mediates hemorrhage-induced intestinal damage. J Surg Res. (2008) 150:196–203. doi: 10.1016/j.jss.2008.02.010

102. Harkin DW, Marron CD, Rother RP, Romaschin A, Rubin BB, Lindsay TF. C5 complement inhibition attenuates shock and acute lung injury in an experimental model of ruptured abdominal aortic aneurysm. Br J Surg. (2005) 92:1227–34. doi: 10.1002/bjs.4938

103. Riedemann NC, Habel M, Ziereisen J, Hermann M, Schneider C, Wehling C, et al. Controlling the anaphylatoxins C5a in diseases requires a specifically targeted inhibition. Clin Immunol. (2017) 180:25–32. doi: 10.1016/j.clim.2017.03.012

104. Kanni T, Zenker O, Habel M, Riedemann N, Giamarellos-Bourboulis EJ. Complement activation in hibernation contributes to proteinuria: a new pathway of pathogenesis? Br J Dermatol. (2018) 179:413–9. doi: 10.1111/bjd.16428

105. Ren J, Zhao Y, Yuan Y, Han G, Li W, Huang Q, et al. Complement depletion deteriorates clinical outcomes of severe abdominal sepsis: a conspirator of infection and coagulopathy in crime? PLoS ONE. (2012) 7:e47095. doi: 10.1371/journal.pone.0047095

106. Neeraer M, Visser T, van Wessem KJ, Koenderman AH, Stengers PF, Koenderman L, et al. The effect of C1-esterase inhibitor on systemic inflammation in trauma patients with a femur fracture - the CAESAR study: study protocol for a randomized controlled trial. Trials. (2011) 12:223. doi: 10.1186/1745-6215-12-223
120. Annane D. Sepsis-associated delirium: the pro and con of C5a blockade. Crit Care. (2009) 13:135. doi: 10.1186/cc7754

121. Mukherjee P, Thomas S, Pasinetti GM. Complement anaphylatoxin C5a neuroprotects through regulation of glutamate receptor subunit 2 in vitro and in vivo. J Neuroinflammation. (2008) 5:5. doi: 10.1186/1742-2094-5-5

122. Zimmerman JL, Dellinger RP, Straube RC, Levin JL. Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit Care Med. (2000) 28:3149–54. doi: 10.1097/00003246-200009000-00004

123. Norda R, Schott U, Berseus O, Akerblom B, Ekdahl KN, et al. Complement activation products in liquid stored plasma and C3a kinetics after transfusion of autologous plasma. Vox Sang. (2012) 102:125–33. doi: 10.1111/j.1423-0410.2011.01522.x

124. Ekdahl KN, Soveri I, Hilborn J, Fellstrom B, Nilsson B. Cardiovascular disease in haemodialysis: role of the intravascular innate immune system. Nat Rev Nephrol. (2017) 13:285–96. doi: 10.1038/nrrneph.2017.17

125. Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. The role of complement in biomaterial-induced inflammation. Mol Immunol. (2007) 44:82–94. doi: 10.1016/j.molimm.2006.06.020

126. Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent JL. Sepsis and septic shock. Nat Rev Dis Primers. (2016) 2:16045. doi: 10.1038/nrdp.2016.45

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Karasu, Nilsson, Köhl, Lambris and Huber-Lang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.